Evidence map›Paper›PMID 38597998›Full record

ArticleBrain tumor pathology2024

Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma.

Kenta Masui, Hiromi Onizuka, Yoshihiro Muragaki, Takakazu Kawamata, Atsushi Kurata, Takashi Komori

Abstract readLetterCase Reports
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Hemizygous deletion ofNeuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kenta MasuiDepartment of Pathology, Tokyo Women's Medical University, Tokyo, Japan. masui-kn@twmu.ac.jp.ORCID http://orcid.org/0000-0002-5824-6690
Hiromi OnizukaDepartment of Pathology, Kyorin University, Tokyo, Japan.
Yoshihiro MuragakiCenter for Advanced Medical Engineering Research and Development, Kobe University, Hyogo, Japan.
Takakazu KawamataDepartment of Neurosurgery, Tokyo Women's Medical University Hospital, Tokyo, Japan.
Atsushi KurataDepartment of Pathology, Tokyo Women's Medical University, Tokyo, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science JP23K06487
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AstrocytomaBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p16Isocitrate DehydrogenaseMutationAdultGene DeletionHumansMaleCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16IDH1 protein, humanIsocitrate DehydrogenaseCDKN2AFISHIDH-mutant astrocytomaIntratumoral heterogeneitySomatic mosaicism

Identifiers

PMID38597998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.